Elan Corporation

Pharmaceutical company

About Us

Products

Elan Drug Technologies

Research & Development

News

Investor Relations

Careers

Governance

• • United States
    • Azactam®
    • Maxipime®
    • PRIALT®
    • TYSABRI® Information Center
• European Union

Tysabri 2005 News Archive

• Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI® in Multiple Sclerosis(11/17/05)
• Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn's Disease and Rheumatoid /Arthritis Patients; TYSABRI Safety Evaluation Complete; No New Confirmed Cases of PML (10/17/05)
• Biogen Idec and Elan Submit Supplemental Biologics License Application to the FDA for TYSABRI® in Multiple Sclerosis(9/26/05)
• Elan and Biogen Idec Provide an Update on TYSABRI® (9/20/05)
• Biogen Idec and Elan Announce TYSABRI® Safety Evaluation Update (8/9/05)
• Two-Year SENTINEL Data Evaluating TYSABRI® in Addition to AVONEX® Reinforce Efficacy in Multiple Sclerosis (7/18/05)
• TYSABRI® Phase III Induction Trial in Crohn's Disease Meets Primary Endpoint; TYSABRI Induced Statistically Significant Response and Remission in Patients with Active Disease (6/30/05)
• Positive One-Year Data From SENTINEL Trial Evaluating Addition of TYSABRI® to AVONEX® Presented at American Academy of Neurology Meeting;Data from GLANCE Safety Study Also Presented (4/13/05)
• TYSABRI® Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression (4/12/05) 
• Elan and Biogen Idec Announce TYSABRI® Update (3/30/05) 
• Biogen Idec and Elan Announce Update on TYSABRI® 3/3/05
• Biogen Idec and Elan Announce Voluntary Suspension of TYSABRI®

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use